Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 42.76
- Piotroski Score 1.00
- Grade Outperform
- Symbol (ELVN)
- Company Enliven Therapeutics, Inc.
- Price $25.43
- Changes Percentage (0%)
- Change -$0
- Day Low $24.69
- Day High $25.76
- Year High $30.03
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $39.50
- High Stock Price Target $40.00
- Low Stock Price Target $39.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.75
- Trailing P/E Ratio -11.97
- Forward P/E Ratio -11.97
- P/E Growth -11.97
- Net Income $-71,584,000
Income Statement
Quarterly
Annual
Latest News of ELVN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Investors are drawn to unprofitable companies like Amazon.com, which despite initial losses, saw significant growth. However, such companies pose risks due to potential cash depletion. Examining Enliv...
By Yahoo! Finance | 2 months ago -
Enliven Therapeutics, Inc. (ELVN) Stock Price, News, Quote & History
Enliven Therapeutics is a biopharmaceutical company in Boulder, CO, developing small molecule inhibitors for cancer treatment. Their lead products, ELVN-001 and ELVN-002, are in Phase 1 trials for chr...
By Yahoo! Finance | 3 months ago
